Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)

May 23, 2019

  • Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressure
  • Data showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months and 23.4 mmHg reduction in office cuff systolic blood pressure out to two years
  • Therapy applicable to a wide range of hypertensive patients including those with isolated systolic hypertension

Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)

April 24, 2019

  • First and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical results
  • Potential to offer significant advantages for treatment of coronary in-stent restenosis (ISR), a condition that represents over 10% of total interventional procedures

Read All News